The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer

BMC Urology

Research Article

Jinsoo Chung¹  Jae Young Joung¹  Sung Han Kim¹  Ho Kyung Seo¹  Jeong Eun Kim¹  Kang Hyun Lee¹  Eun Kyung Hong²  Weon Seo Park² 

[1] Center for Prostate Cancer, National Cancer Center, Goyang, South Korea;Department of Pathology, National Cancer Center, Goyang, South Korea;

关键词: Prostate Cancer;    Radical Prostatectomy;    Androgen Deprivation Therapy;    Complete Pathological Response;    Prostatectomy Specimen;   

DOI  :  10.1186/s12894-015-0079-5

 received in 2015-05-09, accepted in 2015-08-04,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTo identify the prevalence and clinical outcomes of pT0 disease following neoadjuvant hormonal therapy (NHT) and radical prostatectomy (RP) in high-risk prostate cancer.MethodsWe retrospectively included 111 patients who had received NHT and RP for the treatment of high-risk prostate cancer. We classified the patients into two groups, the pT0 group and the non-pT0 group, depending on whether a residual tumor was observed.ResultsWe identified 6 cases (5.4 %) with pT0 disease after reviewing the slides of all patients. There was no recurrence of disease in the pT0 group during a median follow-up of 59 months. Among the 105 patients in the non-pT0 group, biochemical recurrence (BCR) developed in 60 patients (57.1 %), with the median time to BCR being 14 months.ConclusionsAmong the 111 patients with high-risk prostate cancer, we found 6 cases that showed a complete pathological response after NHT and no recurrence of disease during the follow-up, meaning that the androgen deprivation therapy could potentially eradicate high-risk prostate cancer. This is one of the largest studies demonstrating the prevalence of pT0 disease and its outcomes after NHT among patients with high-risk prostate cancer.

【 授权许可】

CC BY   
© Joung et al. 2015